2000
DOI: 10.1001/archderm.136.10.1204
|Get access via publisher |Summarize |Cite
|
Sign up to set email alerts

Bullous Pemphigoid Treated With Leflunomide

Search citation statements

Order By: Relevance

Paper Sections

Select...
23
3
0
0

Citation Types

0
8
0
1

Year Published

2001
2001
2024
2024

Publication Types

Select...
18
5
2

Relationship

0
25

Authors

Journals

citations

Cited by 25 publications

(9 citation statements)
references

References 12 publications

0
8
0
1
Order By: Relevance
How this paper cites the one you are viewing
“…Both patients remained in clinical remission on a 10 mg/day maintenance regimen of leflunomide, which is markedly lower than the usual administered dose in the treatment of rheumatoid arthritis. Therapy was tolerated well with liver enzymes and complete blood counts remained within normal limits 65 . To confirm these preliminary data, further studies with leflunomide as a single agent or in combination therapy regimens should be initiated in the treatment of bullous autoimmune disorders.…”
Section: Bullous Autoimmune Diseases
mentioning
confidence: 68%
How this paper cites the one you are viewing
“…Both patients remained in clinical remission on a 10 mg/day maintenance regimen of leflunomide, which is markedly lower than the usual administered dose in the treatment of rheumatoid arthritis. Therapy was tolerated well with liver enzymes and complete blood counts remained within normal limits 65 . To confirm these preliminary data, further studies with leflunomide as a single agent or in combination therapy regimens should be initiated in the treatment of bullous autoimmune disorders.…”
Section: Bullous Autoimmune Diseases
mentioning
confidence: 68%
How this paper cites the one you are viewing
“…This high initial efficiency of STS in obtaining CCR is reminiscent of the results previously reported by Joly et al with either a standard regimen of clobetasol propionate cream progressively tapered over 12 months or a 'milder' regimen over 4 months only. 20,21 MTX was introduced from the very beginning of STS treatment to avoid any overlap failure between the two phases of treatment and was administered orally in most cases with a median weekly dosage of 10 mg (range [5][6][7][8][9][10][11][12][13][14][15]. The mean and median durations of treatment were 8AE48 months (range 1-18) and 8 months, respectively.…”
Section: Discussion
mentioning
confidence: 99%
How this paper cites the one you are viewing
“…The anecdotal benefits of leflunomide have also been published in case reports of severe atopic dermatitis, 11 sarcoidosis, 12 and bullous pemphigoid. 13 Leflunomide's active metabolite has a long elimination half-life (approximately 2 weeks), reaching a steady state after approximately 20 weeks. Treatment is typically initiated at 20 mg/d.…”
Section: Discussion
mentioning
confidence: 99%